ArticleBioImpacts : BI2025
Immune-modulatory biomimetic nanoparticles: Advances in design, mechanisms, and nanomedicine applications.
Article in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- A Trojan horse nanoplatform overcoming delivery barriers for targeted gene immunotherapy of colorectal cancer.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of biomimetic nanoparticles (NPs) represents an innovative approach to address the lacks of conventional drug delivery systems. This advancement demonstrates promising potential in immunotherapy. Biomimetic NPs imitate biological structures to improve the effectiveness of drug delivery and enhance interactions with cancer cells. Their beneficial features include biocompatibility, long circulation time, tissue specificity, enhanced drug absorption, and low toxicity. Recent advancements confirm the efficacy of biomimetic NPs especially cell-membrane coated biomimetic NPs in immune modulation in cancer and inflammatory diseases. Furthermore, their integration with innovative gene engineering techniques, such as mRNA therapeutics and CRISPR-Cas9, for immune system targeting represents a novel therapeutic approach. This editorial explains the potential of biomimetic NPs in tumor immunotherapy and precision medicine, as well as the challenges they face in clinical translation, including biodistribution, long-term biosafety, the risk of unexpected activation of the immune system and scalability. Future recommendations emphasize the use of advanced biosensing tracking systems and the standardization of production for medicinal translation. BioImpacts invites researchers and scholars involved in this interdisciplinary field to collaborate to advance innovation at the intersection of nanotechnology and immunology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.